Related Experiment Video
Updated: Jul 10, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Management guidelines and outcome measures in giant cell arteritis (GCA)
1Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. warrington.kenneth@mayo.edu
Abstract:
Giant cell arteritis (GCA) is a common form of vasculitis that predominantly affects the elderly. Cranial symptoms and elevated inflammatory markers are suggestive of the condition and the diagnosis is usually established by temporal artery biopsy. Corticosteroids are the mainstay of treatment for GCA and prolonged therapy is often necessary. Disease relapses and steroid-related adverse effects, however, are common. Serious complications of the disease may include visual loss, stroke, and aortic involvement with aneurysm formation.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Atherosclerosis III: Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies